Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.
Vamsidhar Velcheti, MD, director of thoracic medical oncology at NYU Langone Perlmutter Cancer Center, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib (formerly AMG 510) in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC).
The goal of the open-label, single-arm, multicenter, global phase 2 CodeBreaK 100 study was to evaluate sotorasib in a total of 126 patients with KRAS G12C–mutated lung adenocarcinoma, according to Velcheti. Patients enrolled on the trial had previously received treatment with systemic therapies. Of the patients enrolled, 120 had centrally-evaluable scans for RECIST baseline evaluation, says Velcheti.
Results from the primary analysis, which were presented during the 2020 World Conference on Lung Cancer, indicated that sotorasib elicited a confirmed objective response rate of 37.1%. in this population. Among responders, 3 patients achieved a complete response, while 43 experienced confirmed partial responses. The preliminary findings appear to be consistent with previously reported phase 1 data in the same patient population, Velcheti concludes.